$486 Million is the total value of Cormorant Asset Management, LP's 65 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 212.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $121,074,000 | +784.1% | 507,500 | +144.6% | 24.90% | +586.2% |
| RCPT | Buy | RECEPTOS INC | $46,502,000 | +128.0% | 748,700 | +56.4% | 9.56% | +77.0% |
| KERX | New | KERYX BIOPHARMACEUTICALS | $13,750,000 | – | 1,000,000 | +100.0% | 2.83% | – |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $13,320,000 | +199.3% | 850,000 | +183.3% | 2.74% | +132.4% |
| XLRN | Buy | ACCELERON PHARMA INC | $12,096,000 | +78.0% | 400,000 | +100.0% | 2.49% | +38.2% |
| OVAS | New | OVASCIENCE INC | $8,569,000 | – | 516,200 | +100.0% | 1.76% | – |
| BMY | New | BRISTOL MYERS SQUIBB CO | $7,677,000 | – | 150,000 | +100.0% | 1.58% | – |
| GEVA | New | SYNAGEVA BIOPHARMA CORP | $6,878,000 | – | 100,000 | +100.0% | 1.42% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $6,135,000 | – | 100,000 | +100.0% | 1.26% | – |
| ARDX | New | ARDELYX INC | $5,523,000 | – | 388,700 | +100.0% | 1.14% | – |
| ACRX | Buy | ACELRX PHARMACEUTICALS INC | $5,490,000 | -23.5% | 1,000,000 | +42.9% | 1.13% | -40.6% |
| NKTR | New | NEKTAR THERAPEUTICS | $5,432,000 | – | 450,000 | +100.0% | 1.12% | – |
| IMDZ | New | IMMUNE DESIGN CORP | $3,532,000 | – | 200,000 | +100.0% | 0.73% | – |
| KIN | Buy | KINDRED BIOSCIENCES INC | $3,238,000 | +73.7% | 350,000 | +250.0% | 0.67% | +34.8% |
| KITE | New | KITE PHARMA INC | $2,850,000 | – | 100,000 | +100.0% | 0.59% | – |
| AAVL | New | AVALANCHE BIOTECHNOLOGIES IN | $2,222,000 | – | 65,000 | +100.0% | 0.46% | – |
| REPH | Buy | RECRO PHARMA INC | $2,072,000 | -48.3% | 700,000 | +40.0% | 0.43% | -59.8% |
| ZSPH | New | ZS PHARMA INC | $1,962,000 | – | 50,000 | +100.0% | 0.40% | – |
| CLTX | Buy | CELSUS THERAPEUTICS PLCsponsored adr ne | $1,491,000 | +133.3% | 244,500 | +137.4% | 0.31% | +81.7% |
| CLRB | New | CELLECTAR BIOSCIENCES INC | $1,177,000 | – | 530,000 | +100.0% | 0.24% | – |
| ADXS | New | ADVAXIS INC | $1,176,000 | – | 350,000 | +100.0% | 0.24% | – |
| NERV | New | MINERVA NEUROSCIENCES INC | $1,059,000 | – | 175,000 | +100.0% | 0.22% | – |
| New | BRISTOL MYERS SQUIBB CO | $985,000 | – | 5,000 | +100.0% | 0.20% | – | |
| SAGE | New | SAGE THERAPEUTICS INC | $315,000 | – | 10,000 | +100.0% | 0.06% | – |
| CLRBW | New | CELLECTAR BIOSCIENCES INC*w exp 08/19/201 | $318,000 | – | 530,000 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| APELLIS PHARMACEUTICALS INC | 26 | Q1 2024 | 8.6% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| ROCKET PHARMACEUTICALS, INC | 25 | Q1 2024 | 2.4% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rapport Therapeutics, Inc. | June 20, 2024 | 1,283,673 | - |
| CytomX Therapeutics, Inc. | May 13, 2024 | 5,750,000 | - |
| TScan Therapeutics, Inc. | April 29, 2024 | 2,500,000 | - |
| Immuneering Corp | April 15, 2024 | 561,128 | - |
| Ventyx Biosciences, Inc. | March 21, 2024 | 3,670,000 | - |
| Corbus Pharmaceuticals Holdings, Inc. | March 18, 2024 | 2,025,000 | - |
| 89bio, Inc.Sold out | February 14, 2024 | 0 | - |
| Aerovate Therapeutics, Inc.Sold out | February 14, 2024 | 0 | - |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 2,550,000 | - |
| Ambrx Biopharma, Inc. | February 14, 2024 | 8,725,040 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-09-25 |
| 4 | 2024-09-24 |
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.